Skip to content

Study · Not a test of the peptide alone · 2020

2 results

Chlorin A-mediated photodynamic therapy induced apoptosis in human cholangiocarcinoma cells via impaired autophagy flux.

He C, Xia J, Gao Y, Chen Z, Wan X

American journal of translational research15 Sept 2020Cited by 15 (Europe PMC)

PMID33042407 (opens in a new tab)PMCIDPMC7540121 (opens in a new tab)PepBankPUB-33042407
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In cholangiocarcinoma cells, stabilizing mitochondria with elamipretide reduced apoptosis induced by Chlorin A photodynamic therapy.

    In plain wordsIn lab tests on cancer cells, stabilizing mitochondria with elamipretide reduced the cell death caused by a light-activated treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseApoptosis after Chlorin A-PDT with mitochondrial stabilization
    Study

    humann: not reported in source

    Human cholangiocarcinoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Furthermore, mitochondrial dysfunction aggravated ERS, and stabilizing the mitochondria reduced both apoptosis and autophagy.
    1 context sentence
    Summary · context
    The crosstalk between autophagy, endoplasmic reticulum stress (ERS), and mitochondrial dysfunction was investigated using reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC), PERK inhibitor GSK2606414, autophagy inhibitor 3-MA, and mitochondrial stabilizer elamipretide.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In cholangiocarcinoma cells, stabilizing mitochondria with elamipretide reduced autophagy induced by Chlorin A photodynamic therapy.

    In plain wordsIn lab tests on cancer cells, stabilizing mitochondria with elamipretide reduced autophagy caused by a light-activated treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseAutophagy after Chlorin A-PDT with mitochondrial stabilization
    Study

    humann: not reported in source

    Human cholangiocarcinoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Furthermore, mitochondrial dysfunction aggravated ERS, and stabilizing the mitochondria reduced both apoptosis and autophagy.
    1 context sentence
    Summary · context
    The crosstalk between autophagy, endoplasmic reticulum stress (ERS), and mitochondrial dysfunction was investigated using reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC), PERK inhibitor GSK2606414, autophagy inhibitor 3-MA, and mitochondrial stabilizer elamipretide.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.